Matthew Ronsheim is Chief of Pharma Sciences & MFG at Entasis Therapeutics Holdings Inc. (ETTX). They have made 1 open-market trade across 1 company since 2021, most recently 2024-05-20.
CIK 0001824386
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ETTX | SELL | 2021-10-19 | 2021-10-20 | $3.19 | $12K | -1.3% | -11.1% | -35.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.